HLS Therapeutics (TSX:HLS) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:HLS HLS Therapeutics Inc TSX:HLS
67 GF Score
Price C$4.16
GF Value C$4.50
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Net Loan?

Net Loan only applies to banks and insurance companies.

TSX:HLS
67GF Score
HLS Therapeutics Inc TSX:HLS
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.16 is trading 7.6% below its estimated GF Value™ of C$4.50. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Net Loan:
  • GF Value™: C$4.50 vs. price of C$4.16 (7.6% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
67GF Score

Get the complete analysis for TSX:HLS

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.16
Price
C$4.50
GF Value